Literature DB >> 21769601

Eplerenone, an aldosterone antagonist, reduces hospitalization and death in heart failure patients with NYHA class II and an ejection fraction of less than 30%.

Simone Birocchi1, Giulia Carla Luisa Cernuschi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21769601     DOI： 10.1007/s11739-011-0661-0

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  7 in total

1.  Aldosterone and spironolactone in heart failure.

Authors:  K T Weber
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

2.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

3.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

4.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

5.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

6.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

7.  Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice.

Authors:  Giorgio Costantino; Anna Maria Rusconi; Pier Giorgio Duca; Stefano Guzzetti; Ilaria Bossi; Marta Del Medico; Giuseppina Pisano; Mara Bulgheroni; Monica Solbiati; Raffaello Furlan; Nicola Montano
Journal:  Intern Emerg Med       Date:  2008-08-09       Impact factor: 3.397
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.